Based on preliminary encouraging results in terms of response rate and survival, high-dose chemoradiotherapy has gained considerable interest in the treatment of patients with multiple myeloma (MM). We have evaluated the presence of residual myeloma cells in 15 of 18 patients enrolled in a high-dose sequential (HDS) chemoradiotherapy program followed by autografting. Our analysis has been performed both on bone marrow (BM) and peripheral blood (PB) cell harvests and after autografting. As it has been recently shown that B cells clonally related to malignant plasma cells are detectable in MM patients, we have developed a polymerase chain reaction (PCR)-based strategy to detect both residual B cells and plasma cells using clone-specific sequences derived from the rearrangement of lg heavy chain ULTIPLE MYELOMA (MM) is a B-cell malignancy characterized by the expansion of plasma cells producing a monoclonal immunoglobulin.' MM is an incurable disease with a median survival of about 36 months. The standard treatment for MM is a melphalan and prednisone regimen. Extensive clinical trials with other drug combinations have been performed but have not definitively proven to be superior to melphalan and prednisone.'.' In the search for a more effective therapy, several groups have recently used high-dose chemoradiotherapy followed by autologous transplantation, achieving a 50% rate of complete remission. This approach has provided good symptom control, tumor mass reduction, and longer
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In this study, the presence of residual myeloma cells in patients undergoing high-dose sequential (HDS) chemoradiotherapy followed by autografting has been evaluated. It has been recently shown that B cells clonally related to malignant plasma cells are detectable in MM patients. These B cells belong to a maturation stage before Ig heavy chain (IgH) class switching occurs, and they have been regarded as mature B lymphocytes and/or memory B cells (pre-switch B cells).""' We have developed a polymerase chain reaction (PCR)-based strategy to detect both residual B cells and plasma cells using clone-specific sequences derived from the rearranged variable region (VDJ) of IgH genes. The complementarity-determining regions (CDR) of the VDJ region are unique to each B-cell clone and have been used to generate tumor-specific primers and probes." The constant (C) region usage defines the differentiation stage of residual myeloma cells: VDJ sequences are linked to Cp genes in pre-switch B cells, but to Cy or Ca in post-switch B cells (plasma cells)." The presence of clonal pre-and post-switch B cells has been evaluated in 15 of 18 patients enrolled in a pilot HDS chemoradiotherapy program followed by bone marrow (BM) and/or peripheral blood (PB) autologous transplantation. Our analysis has been performed on BM and PB samples at diagnosis, at the time of PB and BM cell harvests. and after autografting.
MATERIALS AND METHODS
Patients and response criteria. Eighteen MM patients at diagnosis (Table 1) were enrolled in an HDS chemoradiotherapy program. Three cycles of dexamethasone, 25 mg/mZ, preceded the HDS regimen. The HDS regimen involved the sequential use of mitoxantrone (escalating doses from 30 to 60 mglm'); etoposide, 2 g/mz; three cycles of dexamethasone, 25 mg/mz; and cyclophosphamide, 7 g/ m'. Dexamethasone cycles before cyclophosphamide were used to allow a complete recovery of BM cellularity for a better mobilization of PB progenitor cells.'" Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF; 5 & k g ) was infused after each drug. After cyclophosphamide treatment, three leukaphereses were performed to harvest PB progenitor cells. Four patients (C.A., F.U., B.L., and B.C.) participated in a previous HDS study in which methotrexate 8 glm' was used instead of mitoxantrone." The myeloablative regimen consisted of melphalan, 120 mglm', and fractionated total body irradiation (10 Gy) (Fig 1) .
Disease response was defined as follows: complete remission (CR): 1% or fewer plasma cells of normal morphology on BM smears and absence of serum and/or urine M protein by immunofixation; partial response (PR): 50% decrease in serum M protein and/or 75% decrease in Bence Jones protein levels; refractory disease was considered in the absence of a decrease in M protein.
Nucleic acid extraction. BM and PB specimens were obtained during standard diagnostic procedures. BM cells and lymphocytes were separated on a Ficoll-Hypaque density gradient. DNA was obtained by cell lysis, phenol extraction, and ethanol precipitation. RNA was isolated by the guanidinium isothiocyanate and cesium chloride centrifugation method.21 Synthesis of cDNA. Two syntheses of cDNA were performed: (1) total RNA was reverse-transcribed using an isotype-specific primer (Ca or Cy) to obtain Ig cDNA (Table 2) , and (2) total RNA was reverse transcribed into total cDNA using an oligo dT-15 primer. Table 2 ). The amplification was performed linking two PCR files: file A: 94°C for 1 minute, 50°C for 
CCAAGCTTCCTGTGCCATCTCCGGGGACAGTG
Restriction sites are underlined. Hindlll for 5' primers and EcoRl for 3' primers. VH.LI through VH.L6, primers derived from the six leader regions; VH.D1 through VH.D6, primers derived from the first framework region.
30 seconds, 72°C for 30 seconds for two cycles; file B: 94°C for 1 minute, 65°C for 30 seconds, 72°C for 30 seconds for 40 cycles, followed by a 7-minute final extension at 72°C. The prevention of PCR contamination was performed as previously described." The 5' primers contained HindIII restriction enzyme sites, while the 3' primer contained an EcoRI site. The PCR product was digested with EcoRI and HindIII enzymes according to the manufacturer's instructions at 37°C for 3 hours. Digested DNA was electrophoresed through a 1.5% low melting point agarose gel, the expected size band was excised, and phenoUchloroform was extracted. An aliquot of digested DNA was directly sequenced using the family-specific VH.L or VH.D and JH.D primers (without restriction sites), as previously described." When the sequence quality did not allow a complete reading of CDR regions, the remaining digested DNA was cloned in a Bluescript SK vector (Stratagene, San Diego, CA) according to standard procedures.21 Restriction enzyme analysis was performed on plasmid DNAs prepared by the alkaline lysis method, and miniprep plasmid DNAs were sequenced as previously described.Z6 Sequence analysis was performed using the PC-GENE software (IntelliGenetics, Inc, Mountain View, CA).
Detection of residual myeloma cells. BM and PB at diagnosis and PB and BM cell harvests were evaluated for the presence of residual myeloma cells. Post-switch B cells were detected as previously described.I3 Briefly, 2 pL of 50 pL of total cDNA was amplified using a 5' primer derived from the CDR2 (Table 3) and a 3' primer from Cy or C a first exon sequence. File C was used for this PCR: 94°C for 1 minute, 58°C for 30 seconds, 72°C for 30 seconds for 45 cycles, followed by a 7-minute final extension at 72°C. A nested-PCR strategy was used to detect pre-switch B cells (Fig 3) . The first amplification was performed using a consensus primer for the variable region (VH.L or VH.D) and a primer from Cp first exon (Cp-5). Of this amplification, 5 pL were reamplified using the internal primers CDR2 and Cp-7." The PCR conditions were as described above. A 30-cycle amplification (file C) was used for both rounds. Twenty percent of the PCR product was analyzed by agarose gel electrophoresis, blotted overnight, and hybridized to CDR3 probes end-labeled with [ Y -~~P ] adenosine triphosphate (ATP) as described previously" ( JH4  JH5  JH4  JH3  JH6  JH4  JH4  JH4  JH4  JH4  JH5  JH4  JH4  JH5  JH4 Abbreviations: FR2, second framework region; JH, joining region. CDRP, 5' primer derived from the second complementarity-determining region.
t CDR3, probe derived from the third complementarity-determining region.
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VDJ region was not amplified, so that only 15 of 18 (83%) could be analyzed for residual disease. The lack of amplification in these three cases may be explained either by the presence of somatic mutations or by the use of unknown variable regions that prevent correct primer/template annealing. In these three cases, alternative strategies for VDJ amplification, such as anchor-PCR and third framework region method. were unsuccessful.'".'" A VDJ amplification rate of 75% was obtained when other B-cell malignancies were used as template (data not shown). Amplified VDJ regions were then sequenced. Direct sequencing analysis provided a good quality sequence in eight cases. For the remaining patients, amplified VDJs were cloned in a plasmid vector. For each patient, I O to 15 clones were sequenced, and together with a few heterogeneous clones, a predominant clone was present in all cases. No intraclonal variation was detected. In patients B.T. and C.A., the sequences, derived from VH.D-amplified DNA, were identical to those obtained in a previous study using an anchor-PCR strategy.26 Concordant results were obtained by both direct sequencing of amplified DNA and after cloning in three patients (B.T., C.A., and F.U.). For each patient, a CDR2 sense primer and a CDR3 probe were synthesized (Table 3 ) and used with a C or JH region primer to detect residual myeloma cells. The use of two tumorspecific oligonucleotides gave identical results in terms of amplification specificity to those obtained using three tumorspecific oligonucleotides in a previous study.'" Several polyclonal lymph nodes were used as negative controls, and no false positive results were detected. Our PCR-based assay could detect one tumor plasma cell in IO6 normal BM cells when cDNA templates were used. Such a sensitivity was achieved performing a serial dilution of tumor plasma cells (from a plasma cell leukemia) with normal bone marrow cells (data not shown). The assay sensitivity is IO times lower when genomic DNA templates are used. Plasma cells contain a large amount of IgH RNA: it was then conceivable to expect a greater sensitivity from cDNA assay. Our results, however, are similar to those obtained with other cDNA assays." A low efficiency of reverse transcription reaction can be a possible explanation of sensitivity data.
Patients outcome. Of the 18 MM patients enrolled in this study, informative VDJ sequences were obtained from 15 patients. Patient A.R. underwent allogeneic transplantation before leukaphereses because of refractory disease. Patient D.G. did not complete the HDS program due to pulmonary mucormycosis, and patient B.R. died of disease progression before cyclophosphamide was administered. Patient C.G. has not been autografted yet. After transplantation, therefore, samples from 12 patients were available for residual disease evaluation: six were in clinical CR (including the allogeneic transplantation), and 6 were in PR. PB and BM samples were collected 4 months after autografting. except for sample from patient P.B., which was collected at day 45 strategy was used to detect pre-switch B cells (Fig 3) . The experimental design involved the analysis of BM and PB cells at diagnosis, after HDS chemotherapy, and after transplantation. As part of the analysis was retrospective, not all samples were available from all patients (Table 4) . In cases where only DNA samples were available for tumor cell detection, pre-switch B-cell analysis could not be performed. After the infusion of cyclophosphamide and rhGM-CSF, three PB and one BM cell harvests were collected for each patient. Pre-switch B cells were detectable in both PB and BM cell harvests of patient A.B. only (Table 4) . It should be noted that RNA samples, to test for the presence of preswitch B cells at diagnosis, were not available for patient F.U. It is unknown whether pre-switch B cells were also absent at diagnosis. On the contrary, post-switch B cells were found in PB (36 of 36) and BM cell harvests (1 2 of 12) from all patients (Table 4) .
After autologous transplantation, post-switch B cells remained detectable in the BM of 12 of 12 tested and in the PB of 10 of 12 tested. In contrast, pre-switch B cells were detected in the BM of 4 of 12 tested and in the PB of 1 of 12 tested. In patient A.R., post-switch B cells were still detectable in BM and PB after allogeneic transplantation (Table 4) .
DISCUSSION
The use of high-dose chemoradiotherapy followed by autologous or allogeneic BM transplantation in the treatment of MM has raised the issue of the assessment of minimal residual disease with a high degree of sensitivity. This is particularly relevant for those patients who achieve a CR phase according to conventional criteria. MM is a tumor affecting primarily the BM. PCR-based studies, however, have recently demonstrated that tumor cells are detectable in the PB of almost all MM patients.".'" As the reinfusion of malignant cells is a major concern in autografting procedures, we decided to evaluate whether residual myeloma cells were present in both BM and PB stem cell harvests used to restore hematopoiesis after the myeloablative treatment. PB stem cells collected by leukaphereses are widely used for myeloma autografting, and they have been considered, so far, safer than BM with respect to the reinfusion of malignant cells."
In the present study, we describe a novel PCR-based strategy to detect residual myeloma cells using clone-specific sequences derived from the rearrangement of IgH genes. Using two sets of primers for the leader and first framework region of the VDJ, the complete sequences of CDR2 and CDR3 were obtained in 83% of cases. The use of a primer derived from the CDR2 and a probe from the CDR3 gave two steps of specificity to the residual disease detection: a tumor-specific amplification and hybridization. We report that post-switch B cells were detectable in BM and PB at diagnosis, at the time of PB and BM cell harvests, and after transplantation in all assessable patients, irrespective of disease status. Pre-switch B cells were detectable in a consistent proportion of BM and PB samples at diagnosis, but only in one case at the time of PB and BM cell harvests. These cells became sometimes detectable after transplantation in both CR and PR patients. The persistence of myeloma cells in stem cell harvests and after autografting does not imply that these cells are clonogenic and contribute to relapse. The potential role played by pre-and post-switch B cells in causing the relapse is at present unknown. However, it should For personal use only. on April 14, 2017. by guest www.bloodjournal.org From be noted that evidence from studies on lymphomas and leukemias support the notion that residual tumor cells contribute to relapse: (1) in low-grade non-Hodgkin's lymphomas, the infusion of residual tumor cells after immunologic purging has been associated with an increased probability of reand chronic myelogenous leukemia have demonstrated that reinfused tumor cells contribute to Pre-switch B cells were not detectable in all but one patient at the time of PB and BM cell harvests. Despite the nonquantitative nature of our assay, the weak signal originating from pre-switch B cells autoradiographically at diagnosis suggests that there are few copies of these transcripts, reflecting a small cell population. It is conceivable that even a moderate cytoreduction reduces the signal below the detection threshold of our assay. The presence of pre-switch B cells after autografting may be explained by the fact that these cells were not eradicated in vivo by the myeloablative regimen, or that they were present in the cell harvests below the detection threshold of our assay and subsequently reinfused. Alternatively, both explanations can be true, and preswitch B cells persisted in vivo and were also reinfused. It is unknown whether pre-switch B cells are clonogenic and then contribute to relapse, feeding plasma cell expansion. In fact, there are no direct experimental proofs of the malignancy of pre-switch B cells. It should be noted, however, that their reappearance after transplantation in three patients in which these cells were not detectable at the time of PB and BM cell harvests suggests that they are proliferating, and they have not been eliminated by treatment.
BM and/or PB stem cells are usually collected after combination chemotherapy and/or a single course of high-dose cyclophosphamide in most of the autotransplantation programs currently in progress.' It should be noted that our PB and BM cell harvests were contaminated by tumor cells even though the collections were performed after HDS chemotherapy. In addition, the constant presence of residual myeloma cells in PB cell harvests rules out the hypothesis that leukaphereses could provide stem cell harvests devoid of myeloma cells. It seems unlikely that tumor cell mobilization is caused by GM-CSF stimulation, as it has been demonstrated that such cells already circulate at diagnosis and during the CR phase.
Whether the achievement of PCR negativity is necessary for cure is still an open question. In the setting of autologous transplantation, where there is no graft-versus-tumor effect, the PCR negativity seems to be a first step to approach longer survival and possible disease eradication." The clonogenic potential of residual myeloma cells as well as the clinical outcome of patients in which pre-and/or post-switch B cells persist after HDS chemotherapy and/or after autografting warrant further studies. Moreover, the disease eradication capability of other high-dose chemotherapy programs, allogeneic transplantation, and antibody-purged and CD34-positive autologous transplantation needs to be evaluated on a large panel of 
